| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR
|
Zhang, Xiangyu
|
|
|
148 |
C |
p. 170-172
|
artikel
|
| 2 |
A reply to “Comment on: ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer”
|
van Veggel, Bianca
|
|
|
148 |
C |
p. 181
|
artikel
|
| 3 |
Are there preinvasive lesions of pulmonary large cell carcinoma?
|
Liu, Shuli
|
|
|
148 |
C |
p. 166-169
|
artikel
|
| 4 |
Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis
|
Ang, Lina
|
|
|
148 |
C |
p. 129-137
|
artikel
|
| 5 |
Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation
|
Bartlett, Emily C.
|
|
|
148 |
C |
p. 12-19
|
artikel
|
| 6 |
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers
|
Yang, Haiyan
|
|
|
148 |
C |
p. 113-121
|
artikel
|
| 7 |
Comment on: ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer’
|
Inagaki, Yuji
|
|
|
148 |
C |
p. 179-180
|
artikel
|
| 8 |
Contents
|
|
|
|
148 |
C |
p. v-vii
|
artikel
|
| 9 |
CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer
|
Suryavanshi, Moushumi
|
|
|
148 |
C |
p. 33-39
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
148 |
C |
p. iii
|
artikel
|
| 11 |
Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma
|
Lin, Yi-Tsz
|
|
|
148 |
C |
p. 177-178
|
artikel
|
| 12 |
Exploring imaging features of molecular subtypes of large cell neuroendocrine carcinoma (LCNEC)
|
Hermans, B.C.M.
|
|
|
148 |
C |
p. 94-99
|
artikel
|
| 13 |
Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma
|
Nakashima, Yasuhiro
|
|
|
148 |
C |
p. 20-27
|
artikel
|
| 14 |
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
|
Peled, Nir
|
|
|
148 |
C |
p. 48-54
|
artikel
|
| 15 |
Improving identification of candidates for lung cancer screening in a high risk population
|
Waddle, Mark R.
|
|
|
148 |
C |
p. 79-85
|
artikel
|
| 16 |
Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE)
|
Marchioni, Alessandro
|
|
|
148 |
C |
p. 40-47
|
artikel
|
| 17 |
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms
|
Rubino, M.
|
|
|
148 |
C |
p. 149-158
|
artikel
|
| 18 |
Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient
|
Kunimasa, Kei
|
|
|
148 |
C |
p. 28-32
|
artikel
|
| 19 |
Necrolytic migratory erythema-like eruption associated with erlotinib in a patient with lung adenocarcinoma
|
Ma, Sheng-Hsiang
|
|
|
148 |
C |
p. 173-174
|
artikel
|
| 20 |
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
|
Reck, Martin
|
|
|
148 |
C |
p. 159-165
|
artikel
|
| 21 |
Novel imprint cytological classification is correlated with tumor spread through air spaces in lung adenocarcinoma
|
Kimura, Toru
|
|
|
148 |
C |
p. 62-68
|
artikel
|
| 22 |
PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry
|
Yoon, Ju-Yoon
|
|
|
148 |
C |
p. 55-61
|
artikel
|
| 23 |
Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation
|
Wei, Qiang
|
|
|
148 |
C |
p. 175-176
|
artikel
|
| 24 |
Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy
|
Okuma, Yusuke
|
|
|
148 |
C |
p. 122-128
|
artikel
|
| 25 |
Proposal of organ-specific subdivision of M component and staging system for metastatic pulmonary neuroendocrine tumor
|
Wen, Junmiao
|
|
|
148 |
C |
p. 86-93
|
artikel
|
| 26 |
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling
|
Madison, Russell
|
|
|
148 |
C |
p. 69-78
|
artikel
|
| 27 |
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
|
Christopoulos, P.
|
|
|
148 |
C |
p. 105-112
|
artikel
|
| 28 |
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
|
Mazzaschi, G.
|
|
|
148 |
C |
p. 1-11
|
artikel
|
| 29 |
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer
|
Suda, Kenichi
|
|
|
148 |
C |
p. 100-104
|
artikel
|
| 30 |
Targeting polyamine as a novel therapy in xenograft models of malignant pleural mesothelioma
|
Lam, Sze-Kwan
|
|
|
148 |
C |
p. 138-148
|
artikel
|
Tijdschrift beschrijving